ArticleTargeted oncology2022

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.

Toshio Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.